Eribulin
- Generic Name
- Eribulin
- Brand Names
- Halaven, Eribulin Baxter, Mevlyq
- Drug Type
- Small Molecule
- Chemical Formula
- C40H59NO11
- CAS Number
- 253128-41-5
- Unique Ingredient Identifier
- LR24G6354G
- Background
Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for use in the treatment of advanced solid tumors .
- Indication
For the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic cancer.
- Associated Conditions
- Metastatic Liposarcoma, Refractory, metastatic Breast cancer, Unresectable Liposarcoma
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer
- Conditions
- HR+HER2- Breast Cancer
- Interventions
- First Posted Date
- 2024-04-03
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 382
- Registration Number
- NCT06343948
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
ELVN-002 with Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer
- Conditions
- HER2-positive Gastric CancerColorectal CancerHER2 AmplificationHER2-positive Breast CancerHER2 Positive Solid Tumors
- Interventions
- First Posted Date
- 2024-03-25
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Enliven Therapeutics
- Target Recruit Count
- 275
- Registration Number
- NCT06328738
- Locations
- 🇮🇹
Azienda Ospedaliero-Universitaria Renato Dulbecco, Catanzaro, Italy
🇺🇸BRCR Medical Center Inc., Plantation, Florida, United States
🇺🇸Washington University, Saint Louis, Missouri, United States
Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical Trial
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2024-03-13
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 81
- Registration Number
- NCT06308939
- Locations
- 🇨🇳
zhejiangCH, Hangzhou, Zhejiang, China
A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
- Conditions
- Triple Negative Breast Cancer
- Interventions
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-06-26
- Target Recruit Count
- 524
- Registration Number
- NCT06279364
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer
- Conditions
- Refractory Breast CarcinomaBreast Cancer
- Interventions
- Other: Organoid-guided personalized treatment
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 302
- Registration Number
- NCT06268652
- Locations
- 🇨🇳
Yanxia Shi, Guangzhou, None Selected, China
A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)
- Conditions
- Sarcoma,Soft Tissue
- Interventions
- First Posted Date
- 2024-02-16
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Intensity Therapeutics, Inc.
- Target Recruit Count
- 333
- Registration Number
- NCT06263231
- Locations
- 🇺🇸
Profound Research LLC, Farmington Hills, Michigan, United States
🇩🇪Universitäres Krebszentrum (UCCL), Leipzig, Germany
🇺🇸USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2024-02-13
- Last Posted Date
- 2024-02-13
- Target Recruit Count
- 200
- Registration Number
- NCT06255392
- Locations
- 🇨🇳
Sun Yat Sen Memorial Hospital，Sun Yat sen University, Guangzhou, Guangdong, China
Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer
- Conditions
- Triple Negative Breast Cancer
- Interventions
- Biological: Cadonilimab
- First Posted Date
- 2024-01-11
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- Shengjing Hospital
- Target Recruit Count
- 128
- Registration Number
- NCT06202313
- Locations
- 🇨🇳
Shengjing Hospital of China Medical University, Shenyang, Liaoning, China
A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer
- Conditions
- Recurrent Breast CancerMetastatic Breast CancerAdvanced Malignancies
- Interventions
- First Posted Date
- 2024-01-11
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 154
- Registration Number
- NCT06202261
- Locations
- 🇨🇳
Affiliated Cancer Hospital of Chongqing University, Chongqing, Chongqing, China
🇨🇳Affiliated cancer hospital of harbin medical university, Harbin, Heilongjiang, China
Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer
- Conditions
- Metastatic Breast Cancer (MBC)
- Interventions
- First Posted Date
- 2023-11-22
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Shanghai Yizhong Pharmaceutical Co., Ltd.
- Target Recruit Count
- 168
- Registration Number
- NCT06143553
- Locations
- 🇨🇳
Jiangsu province Hospital, Nanjing, Jiangsu, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.